source
- BioNTech's CTLA-4 antibody gotistobart shows 8.5-month survival boost in previously treated lung cancer patientsBioNTech reported new data on its CTLA-4 targeting antibody gotistobart in lung cancer. The study focused on patients whose disease had progressed after prior therapy. Those receiving gotistobart…
- Abbott to pay $385 million to settle claims over 2022 baby-formula plant shutdownAbbott Laboratories agreed to a $385 million settlement related to the 2022 shutdown of its Sturgis, Michigan baby-formula plant, the largest in the United States. The plant’s problems triggered a…